Objectives: Infection with co-pathogens is one of the postulated factors contributing to persistent inflammation and non-AIDS events in virologically-suppressed HIV-infected patients. We aimed to investigate the relationship of human herpesvirus-8 (HHV-8), a vasculotropic virus implicated in the pathogenesis of Kaposi's sarcoma, with inflammation and subclinical atherosclerosis in HIV-infected patients.
Introduction
The spectrum of diseases causing morbidity and mortality in HIV-infected persons has shifted from AIDS-defining to non-AIDS related events, similar to those occurring in the general population [1] [2] [3] . This was related to the advent of combination antiretroviral therapy (ART), and its effects on immune dysfunction, lymphocyte activation and inflammation. However, excess morbidity and mortality do occur in HIV-infected compared to uninfected persons, and deaths from cardiovascular and liver diseases, non-AIDS defining cancer and suicide have been reported to be more frequent among patients with highly access to ART [4] . Different reasons have been implicated and, among them, a residual pro-inflammatory status despite effective ART [5, 6] . Several studies support increased immune activation and inflammation among virologically-suppressed HIV patients, and even in elite controllers, compared to the general population [7] [8] [9] [10] .
Infection with co-pathogens is one of the suggested mechanisms contributing to residual chronic inflammation after successful ART. Infections with the Herpesviridiae family are common among HIV-infected and uninfected persons. The relationship of many members of this family with cardiovascular disease has been assessed by measuring different markers of subclinical atherosclerosis and inflammation, and an association has been observed with cytomegalovirus, herpes simplex virus type 2 (HSV-2) and varicella-zoster virus in HIV-infected patients [11] [12] [13] . Human herpesvirus 8 (HHV-8) is a sexually transmitted pathogen highly prevalent among men who have sex with men [14] , although additional transmission routes via saliva, infection during childhood, as well as by blood transfusion, have also been described [15, 16] . HHV-8 is a lymphotropic and vasculotropic herpesvirus linked with Kaposi's sarcoma, and possibly with pulmonary hypertension in HIV-infected patients [17] . Because of the ability of HHV-8-infected vascular endothelial cells to induce the expression of growth factors that cause angiogenesis, endothelial cell proliferation, enhanced vascular permeability, and cytokine production, it had been suggested that HHV-8 could be involved in atherogenesis, but data are very limited [18] . To explore its potential contributing role to the development of non-AIDS related events, and particularly of cardiovascular disease, we aimed to assess whether a relationship exists between HHV-8 and inflammation and subclinical atherosclerosis in virologicallysuppressed HIV-infected patients. To that effect, we analyzed the relationship of HHV-8 with several biomarkers implicated in the pathogenesis of atherosclerosis, including markers of inflammation, endothelial activation, hypercoagulability, immune activation, and oxidative stress. We also evaluated the relationship of HHV-8 with carotid intima-media thickness (c-IMT), and endothelial function through flow-mediated dilatation measurement.
Methods
We conducted a prospective study including consecutive stable HIV-infected patients on ART at increased risk for HHV-8 infection, cared for in an HIV outpatient clinic of a University Hospital in Elche, Spain. Accordingly, during a two-month period, adult (age $18 years) patients who had acquired the HIV through sexual transmission were invited to participate. Previous Kaposi's sarcoma was not an exclusion criterion. To avoid the confounding effect of HIV replication, only patients on ART with virological suppression, defined as a viral load ,200 c/ml, were included in the study. Patients who agreed signed an informed consent before inclusion. The Hospital General Universitario de Elche Ethics Committee (CEIC) approved the protocol.
Clinical data were taken, and blood tests, c-IMT, and endothelial function were obtained after at least an 8 hour overnight fast and smoking abstinence. Self-assessment was used to check smoking abstinence; patients who recognized having smoked in the last 12 hours were given a new appointment for the flow-mediated dilatation test. A sample was processed by centrifugation. Plasma aliquots obtained were stored at 280uC.
Biomarkers measurement
All frozen samples were subsequently defrosted, and plasma levels of vascular cell adhesion molecule-1 (VCAM-1), intercellular CAM-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-a), plasminogen activator inhibitor (PAI-1), sCD14 and sCD163 were measured using commercially available ELISA kits (Quantikine, R&D Systems Europe Ltd, UK). Highly-sensitive C-reactive protein 
Carotid intima-media and flow-mediated dilatation measurement
Endothelial function was evaluated by measuring flow-mediated dilatation of the brachial artery as detailed elsewhere [19] . cIMT measurement was performed as previously described [20] . Measures were taken from both common carotids and bulb portions. Total cIMT was calculated as the mean of all measurements. cIMT was analyzed as a continuous variable, and total cIMT was also categorized according to the median.
Statistical analysis
Differences in demographic and clinical characteristics, in inflammation biomarkers, and in the surrogate atherosclerosis markers between patients with and without HHV-8 were assessed using the chi-squared or Fisher's exact test for categorical variables, and the Mann-Whitney test for continuous variables. The association of HHV-8 with hsCRP, the immune activation markers, and with the cIMT was assessed with linear regression models adjusted for the variables significantly associated with HHV-8 infection (P,0.05) and for the traditional cardiovascular risk factors: age, sex, hypertension, dyslipidemia, diabetes and smoking habit. Anti-platelet therapy was also included in the regression models. For regression analyses, all continuous variables were transformed on the natural log scale (log e ) due to their highly skewed distribution.
Results
157 patients on ART were screened; of them, 140 had an HIV viral load ,200 c/ml, and in 136 serological results for HHV-8 were available. Baseline characteristics are shown in Table 1 . Median (interquartile range) CD4 cell count was 652 (455-863) cell/mm 3 and 634 (441-860) cell/mm 3 in HHV-8 positive and negative patients respectively (P = 0.866). The most frequent antiretroviral regimens contained protease inhibitors (43.4% patients), and non-nucleoside reverse transcriptase inhibitors (NNRTIs) (39% patients); the majority (87.5%) of these patients were also receiving nucleoside reverse transcriptase inhibitors (NRTI), and 19 (17%) integrase inhibitors. Twenty one (15.4%) patients were receiving a raltegravir-based antiretroviral regimen (Table 1) .
Serology tests showed that 34.6% patients were infected with HHV-8. Two patients had a history of previous Kaposi's sarcoma, and no patient had previous diagnosis of Castleman's disease. Prevalence of infection with other herpesviruses is shown in Table 1. HHV-8 infected patients were more frequently co-infected with HSV-2 (P,0.001), and less frequently with hepatitis C virus (HCV) (P = 0.045), and tended to be older (P = 0.086) ( Table 1) .
Relationship of Human herpesvirus-8 with biomarkers
Among blood biomarkers measured, HHV-8-infected patients had higher hsCRP levels (median [ Discussion This is the first study to explore the relationship of HHV-8 infection with inflammation and atherosclerosis in HIV-infected patients. We found that HHV-8 is associated with increased inflammation and immune activation, as reflected by higher levels of hsCRP, CD4/CD38/HLA-DR and CD8/CD38/HLA-DR. The surrogate markers of atherosclerosis assessed in the study, cIMT and endothelial dysfunction, were not different among HHV-8 infected and uninfected patients.
There was a strong association between higher hsCRP levels and HHV-8 infection. hsCRP is the best available cardiovascular risk predictor in head-to-head comparisons of various inflammatory markers, and the only biomarker considered to be an independent predictor of incident coronary heart/cardiovascular disease [21] . Additionally, hsCRP is an exquisitely sensitive and, currently, the more robust and best validated biomarker for lowgrade systemic inflammation. In contrast to other systemic biomarkers, hsCRP is a highly stable molecule falling within a characteristic range for each individual, and it has also shown to remain highly stable when stored at 270uC [22] . Therefore, our findings support a pro-inflammatory state in virologically suppressed HIV-positive patients co-infected with HHV-8. Actually, inflammation induced by HHV-8-infected cells has been implicated in the pathogenesis of multicentric Castleman's disease and other viral-associated malignancies. Disease flares of multicentric Castleman's disease have been associated with elevated levels of a number of cytokines, including viral and human IL-6 or IL-10, and to a lesser degree of TNF-a [23] . Likewise, a systemic inflammatory syndrome in the absence of Castleman's disease has been described in HHV-8-infected patients in association with elevated viral IL-6 levels [24] . HHV-8 was also accompanied in our study by concomitant immune activation, as reflected with the elevation of CD4/CD38/HLA-DR and, to a lesser extent, of CD8/CD38/HLA-DR. Activated CD4 + and CD8 + T cells have been associated with subclinical carotid artery lesions in HIVinfected women [25] .
Infection with other herpesviruses, specifically HSV-2, was also more frequent among the HHV-8-infected patients in our study, probably reflecting the same transmission route. Although HSV-2 has been associated with subclinical atherosclerosis in HIVinfected patients [13] and with elevated hsCRP levels [11] , and a confounding effect could be therefore awaited, the relationship of HHV-8 with inflammation and immune activation remained after adjustment for HSV-2 and for the traditional cardiovascular risk factors. Likewise, the antiretroviral regimen composition could also have an impact in the biomarkers levels, since a proatherogenic profile with PI-based regimes, and anti-atherogenic with integrase inhibitors have been reported [26, 27] . However, the proportion of patients receiving the different ART classes in our study was comparable between HHV-8-infected and uninfected patients.
HHV-8 is a gammaherpesvirus with specific tropism for vascular endothelial cells. To date, the only available clinical data supporting a potential role for HHV-8 in atherosclerosis in HIV- infected patients come from a retrospective analysis of postmortem reports describing a higher frequency of macroscopic atheromatous lesions in patients with Kaposi's sarcoma [18] . Despite the link of HHV-8 with inflammation, we could not demonstrate increased subclinical atherosclerosis through cIMT or endothelial function in HHV-8 coinfected patients. The low number of patients included in the study and, despite adjustment for cardiovascular risk factors and for other herpesviruses, the multifactorial and complex nature of atherosclerotic disease, probably precluded us from finding an independent relationship between HHV-8 infection and both atherosclerosis surrogate markers.
Limitations of the study are the cross-sectional nature of the associations studied, and the number of patients included, which might have been insufficient to show a statistical association between HHV-8 and subclinical atherosclerosis. Although indirect fluorescent assays are the most sensitive tests for HHV-8 detection, no single assay is completely sensitive and specific [28] . Therefore, misclassification of HHV-8 infected and uninfected patients might have occurred.
In summary, our study suggests that HHV-8 infection is associated with increased inflammation and immune activation in virologically suppressed HIV-infected patients. Our study might support a link between HHV-8 infection and inflammation as potential contributing pathogenic factor to the development of non-AIDS related events, including atherosclerotic disease, in HIV-infected patients.
